Rimantadine Kids Syrup 2 mg / ml, 100 ml

Active ingredient: Rimantadine hydrochloride - 2.0 mg.

Excipients: 

sorbitol (liquid sorbitol) - 514.3 mg, 

maltitol (liquid maltitol) - 514.3 mg, 

carmellose sodium - 3.64 mg, 

methyl parahydroxybenzoate - 1.15 mg, 

strawberry flavoring - 0.63 mg, 

purified water - up to 1 ml.

Prevention and early treatment of influenza A in children older than 1 year.

Rimantadine prophylaxis can be effective in contact with patients at home, with the spread of infection in closed groups, and at high risk of the disease during an influenza epidemic.

Treatment Scheme:

It is taken orally (after eating), washed down with water, according to the following scheme: for children from 1 year to 3 years old - on the first day 10 ml (2 teaspoons) of syrup (20 mg) 3 times a day (daily dose - 60 mg) ; 2 and 3 days - 10 ml 2 times a day (daily dose - 40 mg), 4 days - 5 days - 10 ml 1 time a day (daily dose - 20 mg).

Children from 3 to 7 years old - on the first day - 15 ml (3 teaspoons) of syrup (30 mg) j times a day (daily dose - 90 mg); 2 and 3 days - 3 teaspoons 2 times a day (daily dose - 60 mg), 4 days - 5 days - 3 teaspoons 1 time per day (daily dose - 30 mg).

For children from 7 to 10 years old, 25 ml (5 teaspoons) of syrup (50 mg) 2 times a day for 5 days (daily dose is 100 mg).

For children from 11 to 14 years old, 25 ml (5 teaspoons) of syrup (50 mg) 3 times a day for 5 days (daily dose is 150 mg).

Prevention Scheme:

For prevention, apply:

children from 1 year to 3 years - 10 ml (2 teaspoons) of syrup (20 mg) once a day,

children from 3 to 7 years old - 15 ml (3 teaspoons) of syrup (30 mg) once a day,

children over 7 years old - 25 ml (5 teaspoons) of syrup (50 mg) once a day for 10-15 days.

Attention! The daily dose of rimantadine should not exceed 5 mg per kg of body weight.

• Acute liver disease;
• acute and chronic kidney disease;
• thyrotoxicosis;
• pregnancy and the period of breastfeeding;
• children under 1 year old;
• hypersensitivity to rimantadine and the components of the drug;
• sucrose / isomaltase deficiency;
• glucose galactose malabsorption;
• fructose intolerance.

Carefully

Epilepsy (including a history), severe chronic renal failure, liver failure, diabetes mellitus.

Due to the presence of sorbitol in the composition should be taken with caution in case of vomiting, pain and discomfort in the abdomen, diarrhea.

From the cardiovascular system: tachycardia, heart failure,

heart block, palpitations, arterial hypertension, cerebrovascular accident, loss of consciousness.

From the side of the nervous system: insomnia, dizziness, headache, irritability, fatigue, impaired attention, movement disorders, drowsiness, depressed mood, euphoria, hyperkinesia, tremor, hallucinations, confusion, convulsions.

From the sensory organs: tinnitus, change or loss of smell.

From the respiratory system: shortness of breath, bronchospasm, cough.

From the gastrointestinal tract: nausea, vomiting, loss of appetite, dry oral mucosa, abdominal pain, diarrhea, dyspepsia.

From the side of the rut and subcutaneous tissue: rash.

Other: fatigue.

Pharmacodynamic: rimantadine reduces the effectiveness of antiepileptic drugs.

Pharmacokinetic: adsorbents, astringents and enveloping agents reduce the absorption of rimantadine.

Urine acidifying agents (acetazolamide, sodium bicarbonate, etc.) increase the concentration of rimantadine.

Paracetamol and ascorbic acid reduce the maximum concentration of rimantadine in blood plasma by 11%.

Cimetidine reduces the clearance of rimantadine by 18%.

The sorbitol contained in the preparation may affect the bioavailability of the simultaneously used drugs.

Due to the increased risk of dyspeptic symptoms, simultaneous administration with other medicines containing sorbitol is not recommended.

In some cases, when the recommended dose is exceeded, tearing of the eyes and pain in the eyes, frequent urination, fever, constipation, sweating, inflammation of the oral mucosa, dry skin are observed.

Treatment: gastric lavage, symptomatic therapy: measures to maintain vital functions. Rimantadine is partially excreted during hemodialysis.

The use of rimantadine within 2-3 days before and 6-7 hours after the onset of clinical manifestations of type A influenza reduces the severity of the symptoms of the disease and the degree of serological reaction. Some therapeutic effect may also occur if rimantadine is prescribed within 18 hours after the onset of the first symptoms of influenza.

When applying, an exacerbation of chronic concomitant diseases is possible.

In patients with epilepsy with rimantadine, the risk of developing an epileptic seizure increases. 15 ml of syrup corresponds to 1 bread unit (XE), which should be considered when prescribing the drug to patients with diabetes.

Perhaps the emergence of drug-resistant viruses.

Sorbitol can cause abdominal discomfort and a laxative effect. In the event of the development of such effects during treatment, the drug should be discontinued and consult a doctor.

Due to the increased risk of dyspeptic phenomena, simultaneous intake with food products containing significant amounts of sorbitol (prunes, etc.) is not recommended.

Impact on the ability to drive vehicles and mechanisms

Given the likelihood of side effects from the central nervous system, caution should be exercised when driving vehicles and mechanisms.